Just Who Is Dr. Clay Siegall

The fight against cancer is at an all-time high. This deadly disease can manifest from many vital organs within the body. Cancer research is also at an all-time high, and it is producing medications that are very effective for fighting this disease. One of the biggest and best cancer research institutions in the world is known as Seattle Genetics. This company has been around since the late 1990s, and it has made huge progress in this demanding sector of business. Dr. Clay Siegall is the company’s CEO and president. He has provided the proper leadership and guidance that is needed to operate such a brilliant machine. The company has done so well over the past few years that its stock has roughly tripled.

Dr. Siegall is the man with the plan, and he uses this plan to save lives. How does he do it? Seattle Genetics produces the top cancer fighting medications in the world. Anti-body Drug Conjugates are designed to seek out and to destroy cancerous cells within the human body. These medications gives cancerous cells a powerful death blow, which eradicates it. Another great feature of (ADCs) is that they aren’t as harsh as previous medications like chemotherapy. The side effects of chemotherapy can make the patient feel as sick as the disease itself. Dr. Siegall is shaking up the industry because his company has many more advanced medications already in the pipeline. Its current premium drug ADCETRIS, has a multiple license deal with other major pharmaceutical giants like Pfizer and GlaxoSmithKline. This deal is actually a license agreement, and with this agreement, the medications can be distributed throughout the world. There’s no wonder why the companies stock has risen so high.

Dr. Siegall is one of the most trusted individuals of this industry, and his passion to save lives can be felt. He is simply focused on the task at hand. By having so much cutting-edge technology on deck, Seattle Genetics doesn’t look to be slowing down anytime soon.

 

Leave a Reply

Your email address will not be published. Required fields are marked *